1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, June 2018 (p9)

Healthcare Analysis & Statistics in the United States, June 2018 (p9)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

241-264 of about 300 reports

Bempedoic Acid Franchise

Bempedoic Acid Franchise

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewBempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis. It is believed to work by inhibiting ATP citrate lyase (ACL) and by interacting ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Gocovri

Gocovri

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewGocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Xadago

Xadago

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewXadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Duopa

Duopa

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAbbVie’s Duopa, a continuous intestinal infusion of a carbidopa plus levodopa gel, is indicated for the treatment of advanced-stage idiopathic Parkinson’s disease with motor fluctuations ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
ND0612

ND0612

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewThe ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H. ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union
Rytary

Rytary

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewRytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component. Rytary is dosed ...

  • Industries : Mental Health, Pathology
  • Countries : United States
APL-130277

APL-130277

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAPL-130277 (Dainippon Sumitomo/Sunovion)  is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist. It is being developed for the on-demand treatment of “off” ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Azilect

Azilect

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAzilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, Europe, Japan, European Union
Neupro

Neupro

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewNeupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Nouriast

Nouriast

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewNouriast (istradefylline; Kyowa Hakko Kirin) is the first, and so far, the only adenosine A2a receptor antagonist to be approved for the treatment of Parkinson’s disease. It acts to decrease ...

  • Industries : Mental Health, Pathology
  • Countries : Japan, United States
Inbrija

Inbrija

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewInbrija (Acorda Therapeutics) is an inhaled formulation of levodopa, in development as an adjunct to existing oral levodopa formulations in patients experiencing motor fluctuations. Levodopa ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Europe
Ongentys

Ongentys

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewOngentys (Neurocrine/Bial/Ono Pharmaceutical) is a once-daily formulation of the catechol-O-methyltransferase (COMT) inhibitor opicapone, approved as an add-on therapy to levodopa for the ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union, North America
Oncology: Surgical Ablation Devices Market

Oncology: Surgical Ablation Devices Market

  • $ 4750
  • Industry report
  • June 2018

OVERVIEWValued at approximately $380m in 2017, the Surgical Ablation Devices Market for Oncology is expanding at a double-digit rate, driven by the increasing global prevalence of cancer and the growing ...

  • Industries : Cancer, Pathology
  • Countries : World, United States, Japan
Systemic Hypertension Market and Forecast Analysis to 2027

Systemic Hypertension Market and Forecast Analysis to 2027

  • $ 22000
  • Industry report
  • June 2018

DISEASE OVERVIEWAs the most common risk factor for cardiovascular diseases, hypertension is the costliest primary and secondary healthcare condition worldwide. Hypertension refers to persistent, abnormally ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, Japan, European Union
Wound Care: Advanced Dressings and Closure Products

Wound Care: Advanced Dressings and Closure Products

  • $ 4750
  • Industry report
  • June 2018

OVERVIEWMarkets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. ...

  • Industries : Medical Supply
  • Countries : World, United States
Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • June 2018

DISEASE OVERVIEWGlioblastoma (GBM) is the most common and most aggressive type of malignant primary brain tumor. It is a malignant glioma that develops from astrocytes, which are star-shaped glial cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Diagnostic Electrocardiograph Products

Diagnostic Electrocardiograph Products

  • $ 4750
  • Industry report
  • June 2018

OVERVIEWThe global market for diagnostic electrocardiograph products is anticipated to see high, single-digit growth throughout the forecast period covered by this analysis (2017-22). Growth in unit sales is ...

  • Industries : Patient Monitoring
  • Countries : World, Japan, United States
Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023

Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • Industry report
  • May 2018

DISEASE OVERVIEWOvarian cancer is defined as a group of tumors that originate in the ovaries. Epithelial ovarian cancer is the prevailing cause of death from gynecological malignancies in the Western world. ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Simponi

Simponi

  • $ 10000
  • Industry report
  • May 2018

Drug OverviewSimponi (golimumab; Johnson and Johnson/Merck and Co/Mitsubishi Tanabe) is a second-generation TNF inhibitor following Johnson and Johnson’s Remicade (infliximab). It is a fully human monoclonal ...

  • Industries : Pathology, Therapy, Medical Biotechnology
  • Countries : United States, Japan, European Union
Taltz

Taltz

  • $ 10000
  • Industry report
  • May 2018

Drug OverviewTaltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17. It gained approval from the US Food and ...

  • Industries : Pathology
  • Countries : United States, Japan, European Union
Enbrel

Enbrel

  • $ 10000
  • Industry report
  • May 2018

Drug OverviewEnbrel (etanercept; Amgen/Pfizer/Takeda) is a dimeric fusion protein consisting of the extracellular ligand binding portion of tumor necrosis factor (TNF) receptor linked to the Fc portion ...

  • Industries : Medical Biotechnology, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Geodon

Geodon

  • $ 10000
  • Industry report
  • April 2018

Drug OverviewGeodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer. Geodon initially launched in the US in 2001 for the treatment of schizophrenia. ...

  • Industries : Mental Health, Pathology
  • Countries : Japan, United States
2018 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ACC Report, Pharma Intelligence

2018 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ACC Report, Pharma Intelligence

  • $ 599
  • Industry report
  • April 2018

The American College of Cardiology (ACC) 67th Scientific Session was held in Orlando, FL from 10–12 March 2018.The highlight of this year’s conference was results from Praluent’s (REGN, SNY) ODYSSEY ...

  • Industries : Chronic Disease
  • Countries : United States
Bevyxxa

Bevyxxa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewBevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness. It is currently the only anticoagulant ...

  • Industries : Health Services
  • Countries : United States

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on